BRCA1 and BRCA2 Mutations and Their Clinical Relevance in Selected Women Diagnosed with Triple-negative Breast Cancer in Kenya: a Descriptive Cross-sectional Study

Overview

Journal Pan Afr Med J

Date 2023 Sep 18

PMID 37719058

Authors

Josephine Nyabeta Rioki

Lucy Muchiri

Marshal Mweu

Joshua Nyagol

Elijah Songok

Joseph Mwangi

Micah Oyaro

Laban Bwire Ongango

Emily Rogena

Affiliations

Soon will be listed here.

Abstract

Introduction: triple-negative breast cancer (TNBC) is a heterogeneous breast cancer type with a poor prognosis. About 25% of TNBC patients carry breast cancer susceptibility genes 1 and 2 (BRCA1 and BRCA2) mutations. Screening for BRCA mutations would facilitate early detection and initiation of personalized therapy, thus improving prognosis. However, this has not been explored in our population. We aimed at identifying BRCA1 and BRCA2 gene mutations and their clinical relevance among selected women with TNBC in Kenya.

Methods: six participants enrolled in a larger descriptive cross-sectional study who met the inclusion criteria were selected. Structured questionnaires were used to obtain qualitative data. Deoxyribonucleic acid (DNA) was extracted from saliva. Whole exome sequencing of BRCA1 and BRCA2 genes using a next-generation sequencer was done.

Results: overall, 83.3% of BRCA1 and BRCA2 gene mutations with clinical relevance were detected. Most of the variants (63%) were found in BRCA1 whereas 37% were found in BRCA2. Pathogenic mutations in BRCA1 gene included c.5513T>A, c.5291T>C, c.5297T>G, c.110C>A, c.5212G>C, c.122A>C, c.5117G>A, c.5095C>T, c.5054C>T, c.5053A>G, c.115T>A, c.5143A>G, and c.130T>G. Those in BRCA2 gene were c.7878G>A, c.9154C>T, c.8243G>A, c.7976G>A, c.8165C>G, c.8167G>C, and c.8168A>T. One variant (c.5352delG: p. Leu1785Terfs) not matching any in the BRCA Exchange and ClinVar databases was detected.

Conclusion: our study revealed BRCA mutations that could be common among our population. Further, it has shown that BRCA1 and BRCA2 genetic mutations identified are of clinical relevance and there is a need to screen for these mutations in breast cancer patients to understand their implication in patient management outcomes.

References

Colombo M, De Vecchi G, Caleca L, Foglia C, Ripamonti C, Ficarazzi F . Comparative in vitro and in silico analyses of variants in splicing regions of BRCA1 and BRCA2 genes and characterization of novel pathogenic mutations. PLoS One. 2013; 8(2):e57173. PMC: 3579815. DOI: 10.1371/journal.pone.0057173. View

Mavaddat N, Antoniou A, Easton D, Garcia-Closas M . Genetic susceptibility to breast cancer. Mol Oncol. 2010; 4(3):174-91. PMC: 5527934. DOI: 10.1016/j.molonc.2010.04.011. View

Colditz G, Kaphingst K, Hankinson S, Rosner B . Family history and risk of breast cancer: nurses' health study. Breast Cancer Res Treat. 2012; 133(3):1097-104. PMC: 3387322. DOI: 10.1007/s10549-012-1985-9. View

Evans O, Gaba F, Manchanda R . Population-based genetic testing for Women's cancer prevention. Best Pract Res Clin Obstet Gynaecol. 2020; 65:139-153. DOI: 10.1016/j.bpobgyn.2020.02.007. View

Imyanitov E, Sokolenko A . Mechanisms of acquired resistance of BRCA1/2-driven tumors to platinum compounds and PARP inhibitors. World J Clin Oncol. 2021; 12(7):544-556. PMC: 8317650. DOI: 10.5306/wjco.v12.i7.544. View

Karami F, Mehdipour P . A comprehensive focus on global spectrum of BRCA1 and BRCA2 mutations in breast cancer. Biomed Res Int. 2013; 2013:928562. PMC: 3838820. DOI: 10.1155/2013/928562. View

Cocco S, Piezzo M, Calabrese A, Cianniello D, Caputo R, Lauro V . Biomarkers in Triple-Negative Breast Cancer: State-of-the-Art and Future Perspectives. Int J Mol Sci. 2020; 21(13). PMC: 7369987. DOI: 10.3390/ijms21134579. View

Mosalpuria K, Hall C, Krishnamurthy S, Lodhi A, Hallman D, Baraniuk M . Cyclooxygenase-2 expression in non-metastatic triple-negative breast cancer patients. Mol Clin Oncol. 2014; 2(5):845-850. PMC: 4106732. DOI: 10.3892/mco.2014.327. View

Hamdi Y, Mighri N, Boujemaa M, Mejri N, Ben Nasr S, Ben Rekaya M . Identification of Eleven Novel Mutations in Tunisia: Impact on the Clinical Management of Related Cancers. Front Oncol. 2021; 11:674965. PMC: 8417726. DOI: 10.3389/fonc.2021.674965. View

10.

Lovejoy L, Turner C, Wells J, Shriver C, Ellsworth R . Heritability of Low ER Staining/HER2-Breast Tumors: Are We Missing an Opportunity for Germline Testing?. Genes (Basel). 2020; 11(12). PMC: 7763582. DOI: 10.3390/genes11121469. View

11.

Brewer H, Jones M, Schoemaker M, Ashworth A, Swerdlow A . Family history and risk of breast cancer: an analysis accounting for family structure. Breast Cancer Res Treat. 2017; 165(1):193-200. PMC: 5511313. DOI: 10.1007/s10549-017-4325-2. View

12.

Findlay G, Daza R, Martin B, Zhang M, Leith A, Gasperini M . Accurate classification of BRCA1 variants with saturation genome editing. Nature. 2018; 562(7726):217-222. PMC: 6181777. DOI: 10.1038/s41586-018-0461-z. View

13.

Zhong A, Xia K, Hadjis Z, Lifman G, Njambi L, Dimaras H . Opportunities and barriers for genetic service delivery in Kenya from a health personnel perspective. J Community Genet. 2021; 12(4):525-538. PMC: 8257851. DOI: 10.1007/s12687-021-00532-5. View

14.

Pogoda K, Niwinska A, Sarnowska E, Nowakowska D, Jagiello-Gruszfeld A, Siedlecki J . Effects of Germline Mutations on Triple-Negative Breast Cancer Prognosis. J Oncol. 2020; 2020:8545643. PMC: 7165358. DOI: 10.1155/2020/8545643. View

15.

Song C, Teo S, Taib N, Yip C . Surgery for , TP53 and PALB2: a literature review. Ecancermedicalscience. 2018; 12:863. PMC: 6113980. DOI: 10.3332/ecancer.2018.863. View

16.

Yoo J, Lee G, Kim J, Lee S, Chae H, Han E . Clinical Validity of Next-Generation Sequencing Multi-Gene Panel Testing for Detecting Pathogenic Variants in Patients With Hereditary Breast-Ovarian Cancer Syndrome. Ann Lab Med. 2019; 40(2):148-154. PMC: 6822011. DOI: 10.3343/alm.2020.40.2.148. View

17.

Rashid M, Muhammad N, Bajwa S, Faisal S, Tahseen M, Lorenzo Bermejo J . High prevalence and predominance of BRCA1 germline mutations in Pakistani triple-negative breast cancer patients. BMC Cancer. 2016; 16(1):673. PMC: 4995655. DOI: 10.1186/s12885-016-2698-y. View

18.

Rajagopal T, Seshachalam A, Jothi A, Rathnam K, Talluri S, Venkatabalasubranian S . Analysis of pathogenic variants in BRCA1 and BRCA2 genes using next-generation sequencing in women with triple negative breast cancer from South India. Mol Biol Rep. 2022; 49(4):3025-3032. DOI: 10.1007/s11033-022-07129-2. View

19.

Morris G, Naidu S, Topham A, Guiles F, Xu Y, McCue P . Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: a single-institution compilation compared with the National Cancer Institute's Surveillance, Epidemiology, and End Results database. Cancer. 2007; 110(4):876-84. DOI: 10.1002/cncr.22836. View

20.

Dent R, Trudeau M, Pritchard K, Hanna W, Kahn H, Sawka C . Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007; 13(15 Pt 1):4429-34. DOI: 10.1158/1078-0432.CCR-06-3045. View